Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Angela Rose Brannon"'
Autor:
Jason C. Chang, Alan Li, Ian Johnson, Charles M. Rudin, David N Brown, Snjezana Dogan, Preethi Srinivasan, Julie L. Yang, Aijazuddin Syed, Meera Hameed, JinJuan Yao, Aaron Agarunov, Emily S. Lebow, Chad M. Vanderbilt, Christine Moung, Rohit Sharma, David B. Solit, Efsevia Vakiani, Anna Razumova, Bob T. Li, Monica Diosdado, James J. Harding, Mohammad Haque, Wassim Abida, Marc Ladanyi, Michael F. Berger, Anita S. Bowman, Dilmi Perera, Dennis Stephens, Luis A. Diaz, Brian J. Murphy, Benjamin A. Krantz, Maria E. Arcila, Tejus Bale, Ryan Ptashkin, Gopa Iyer, Helena A. Yu, Eileen M. O'Reilly, Angela Rose Brannon, Aliaksandra Samoila, Khedoudja Nafa, Dana Tsui, Maysun Hasan, Erika Gedvilaite, Sarat Chandarlapaty, Tessara Baldi, Lillian M. Smyth, Brian Houck-Loomis, Juber Patel, Yu Hu, Ryma Benayed, Helen Won, Ivelise Rijo, Nicole DeGroat, Jaclyn F. Hechtman, Douglas A. Mata, Justyna Sadowska, Dara S. Ross, Jamal Benhamida, Gowtham Jayakumaran, Ying Liu, Fanli Meng, Donna C. Ferguson, Pedram Razavi, Anoop Balakrishnan Rema, Ahmet Zehir, Soo-Ryum Yang, Xiaohong Jing, Jenna-Marie Dix
Circulating cell-free DNA (cfDNA) from blood plasma of cancer patients can be used to interrogate somatic tumor alterations non-invasively or when adequate tissue is unavailable. We have developed and clinically implemented MSK-ACCESS (Analysis of Ci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::678ac8daac5ab721d94a6f9a62c5eab1
https://doi.org/10.1101/2020.06.27.175471
https://doi.org/10.1101/2020.06.27.175471
Autor:
Andrew T. Lenis, Min Yuen Teo, Gopa Iyer, Michael F. Berger, David H. Aggen, Jonathan E. Rosenberg, Ziyu Chen, Hikmat Al-Ahmadie, Dean F. Bajorin, Ashley Marie Regazzi, Michal Sarfaty, David B. Solit, Angela Rose Brannon, Neha Ratna, Samuel Funt, Chung-Han Lee
Publikováno v:
Journal of Clinical Oncology. 39:e16519-e16519
e16519 Background: The pan-FGFR inhibitor erdafitinib (erda) is FDA-approved for pretreated mUC pts harboring FGFR2/3 alterations. We explored concordance of FGFR3 alt profiles between primary tumor and cfDNA using the next generation sequencing assa
Autor:
Charles M. Rudin, Mark T.A. Donoghue, Paul K. Paik, Michael F. Berger, James M. Isbell, Michael Offin, Angela Rose Brannon, Ryma Benayed, Gowtham Jayakumaran, Bob T. Li, David B. Solit, David R. Jones, Azadeh Namakydoust, Yonina R. Murciano-Goroff, Emily S. Lebow, Alexander Drilon, Ahmet Zehir, Ronglai Shen, Helena Alexandra Yu, Justin Jee
Publikováno v:
Journal of Clinical Oncology. 39:9009-9009
9009 Background: The effectiveness of circulating tumor DNA (ctDNA) at matching patients to life prolonging therapy has been studied mostly in small cohorts with limited follow up. The prognostic value of ctDNA alterations, particularly those absent
Autor:
Dana W.Y. Tsui, David B. Solit, Yonina R. Murciano-Goroff, Maria E. Arcila, Charles M. Rudin, Emily S. Lebow, Mark G. Kris, Michael F. Berger, Angela Rose Brannon, Bob T. Li, Marc Ladanyi, Jorge S. Reis-Filho, Pedram Razavi, Jamie E. Chaft, Ahmet Zehir, David R. Jones, Daniel R. Gomez, James M. Isbell, Alexander Drilon, Ryma Benayed
Publikováno v:
Journal of Clinical Oncology. 38:3529-3529
3529 Background: Circulating cell-free DNA (cfDNA) next-generation sequencing (NGS) is a promising strategy for non-invasive molecular profiling of cancers. MSK-ACCESS (Analysis of Circulating cfDNA to Evaluate Somatic Status) is a hybridization-capt
Autor:
Neha Ratna, Michael F. Berger, Hikmat Al-Ahmadie, David H. Aggen, Ashley Marie Regazzi, Angela Rose Brannon, Min Yuen Teo, David B. Solit, Gopa Iyer, Samuel Funt, Chung-Han Lee, Jonathan E. Rosenberg, Dean F. Bajorin, Michal Sarfaty
Publikováno v:
Journal of Clinical Oncology. 38:e17034-e17034
e17034 Background: The pan-FGFR inhibitor erda was recently FDA-approved for pretreated mUC pts harboring FGFR2/3 alterations. We explored concordance of FGFR3 mutation profiles between the primary tumor and cfDNA using the MSK-ACCESS platform. We al
Autor:
Michael F. Berger, Oscar Lin, Maria E. Arcila, Gopakumar Iyer, Angela Rose Brannon, Sasinya N. Scott
Publikováno v:
Journal of the American Society of Cytopathology. 2:S82-S83
Autor:
Michael F. Berger, Can G. Pham, Sasinya N. Scott, James J. Hsieh, Angela Rose Brannon, A. Ari Hakimi, Martin H. Voss, Ying-Bei Chen, Shugaku Takeda, Han Liu, Robert J. Motzer
Publikováno v:
Journal of Clinical Oncology. 31:4573-4573
4573 Background: Rapalogs, inhibitors of mTOR, are approved for treatment of advanced RCC. Recent reports of clonal heterogeneity challenge the concept of targeted monotherapy and the development of genomic biomarkers. Still, a subset of patients (pt
Autor:
Matthew E. Nielsen, Jennifer C. Fisher, Kimryn Rathmell, Samira A. Brooks, Angela Rose Brannon, Joel S. Parker, Oishee Sen
Publikováno v:
Journal of Clinical Oncology. 31:4522-4522
4522 Background: The objective of this study is to create a molecular tool that can be applied widely to clinical specimens using existing transcript signatures for use in clinical risk prediction of clear cell Renal Cell Carcinoma (ccRCC) to improve